What's Happening?
The Federal Trade Commission (FTC) has issued a consent order with Express Scripts, marking a significant restructuring of the pharmacy benefit manager (PBM) industry. This order is part of a broader effort to reform the rebate-driven PBM model, which
has been under scrutiny for its impact on drug pricing and market dynamics. The consent order, effective by January 1, 2028, introduces changes across four key areas: formulary and pricing, plan sponsor options, transparency, and reshoring. Express Scripts is required to eliminate practices that favor high-cost drug versions over cheaper alternatives and to delink manufacturer compensation from list prices. Additionally, the company must offer plan sponsors a standard benefit design based on net drug costs and provide access to a new federal low-cost prescription drug platform. The order also mandates the reshoring of Express Scripts' group purchasing organization, Ascent Health Services, from Switzerland to the U.S., bringing over $750 billion in purchasing activity back to domestic jurisdiction.
Why It's Important?
This consent order represents a pivotal shift in the PBM industry, addressing long-standing concerns about the role of PBMs in inflating drug prices. By restructuring economic incentives and enhancing transparency, the FTC aims to create a more equitable and efficient drug pricing system. The changes are expected to benefit consumers by reducing out-of-pocket costs and increasing access to affordable medications. The reshoring of purchasing activities also has significant economic implications, potentially boosting domestic job creation and investment. The order's impact extends beyond Express Scripts, as it sets a precedent for other PBMs, potentially leading to broader industry reforms. The settlement aligns with the administration's broader drug pricing strategy, emphasizing transparency and cost-based reimbursement models.
What's Next?
The consent order is subject to a 30-day public comment period, allowing stakeholders to provide input before the FTC finalizes the order. The outcome of this process could influence the final compliance provisions. Additionally, a pending constitutional challenge in the U.S. Court of Appeals for the Eighth Circuit could affect the procedural landscape for FTC enforcement actions. The industry will be closely watching whether other PBMs reach similar settlements with the FTC, which could further reshape the healthcare market. The long-term success of these reforms will depend on effective implementation and oversight, as well as the willingness of other industry players to adopt similar practices.
